Monte Rosa Therapeutics, Inc
Monte Rosa Therapeutics seeks a HighThroughput Cellular Assay expert to contribute to developing targeted protein degradation methods to eliminate disease-causing proteins.
Monte Rosa Therapeutics is a biotechnology company pioneering molecular glue degrader (MGD) therapies that promote specific protein ubiquitination and subsequent proteasomal degradation of disease-causing, traditionally undruggable proteins. Their drug discovery platform integrates expertise in MGD chemistry, artificial intelligence, structural biology, and proteomics to rapidly advance programs targeting undruggable or inadequately drugged targets with unprecedented specificity. Focused on cancer and beyond, the company operates out of Boston, MA and Basel, Switzerland.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc didn’t post a salary, so this is our estimate from similar listings.
Principal Scientist – Lead Discovery and Targeted Protein Degradation Biochemistry
Amgen
Associate Scientist II/Senior Associate Scientist Biology
Iambic Therapeutics
Senior Research Scientist Platform Biology
Arvinas
Principal Biologist
Proxima
Molecular Pharmacology Scientist
Miami-Dade County
Molecular Pharmacology Scientist
New York State